Hi Ice never disgard Abbott labs , they might have something simmilar but how well is their anticalcification treatment working and does it have the Data to compete with the ADAPT . At the end of the day Abbott’s are far more cashed up than any of their competitors and if they see a definite advantage in acquiring AVRs TAVR and ADAPT IP they could still possibly be a player . Just think to yourself , how much money Abbots have spent to develop their TAVR ? It would not be anywhere near 1 Billion . IMO Abbott’s are not there to run second or third in a 10 Billion dollar market . If AVRs TAVR has substantial benefits to theirs Abbots will be in the game. Just bear in mind Abbots would be the best positioned to take advantage of the ADAPT platform as well . I am still not discounting a company none of us are even thinking of acquiring AVR . Exciting times ahead GLTATH
AVR Price at posting:
$25.29 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)